Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib plus Durvalumab in Stage III NSCLC
NCT04895579Phase 1Completed
- Start
- May 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copanlisib in non-small cell lung cancer (NSCLC). Primary endpoint: Dose Limiting Toxicity at 28 days. Started May 2021; status: completed.
02
Drugs
copanlisib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04895579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895579.